Opaviraline

CAS No. 178040-94-3

Opaviraline( —— )

Catalog No. M34360 CAS No. 178040-94-3

Opaviraline (GW-420867X) is a potent reverse transcriptase inhibitor that inhibits Human immunodeficiency virus 1 and has the potential to treat HIV infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 824 In Stock
5MG 922 In Stock
10MG 1226 In Stock
25MG 1853 In Stock
50MG 2437 In Stock
100MG 3283 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Opaviraline
  • Note
    Research use only, not for human use.
  • Brief Description
    Opaviraline (GW-420867X) is a potent reverse transcriptase inhibitor that inhibits Human immunodeficiency virus 1 and has the potential to treat HIV infection.
  • Description
    Opaviraline (GW-420867X) is a potent reverse transcriptase inhibitor that inhibits Human immunodeficiency virus 1 and has the potential to treat HIV infection.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    178040-94-3
  • Formula Weight
    280.29
  • Molecular Formula
    C14H17FN2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(OC(C)C)(=O)N1C=2C(NC(=O)[C@@H]1CC)=CC=C(F)C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Peptide T TFA

    Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

  • DMJ-I-228

    A small molecule CD4-mimetic that binds gp120 and blocks CD4 binding, inhibits HIV-1 entry with IC50 of 86.9 uM.

  • Tipranavir

    Tipranavir is a protease inhibitor that inhibits HIV-1 resistant to more than 1 protease inhibitor .